2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Daniel A. Vorobiof, MD, the chief medical director of Belong.Life, discusses the impact of financial toxicity on patients with cancer.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Daniel A. Vorobiof, MD, the chief medical director of Belong.Life, discusses the impact of financial toxicity on patients with cancer.
Financial toxicity has become a growing concern for several patients with cancer, as well as their caregivers, says Vorobiof. As treatment costs continue to rise, Vorobiof says that financial toxicity is a challenge that can no longer be ignored. A cancer diagnosis is often accompanied by substantial financial burden, and although this is not a new issue, it must be addressed, Vorobiof says.
Real-world data from several clinical studies indicate that financial toxicity is a major factor that impacts outcomes and the quality of life of patients, spanning different tumor types and treatments received, Vorobiof concludes.
Related Content: